A multicenter, open-label, randomized phase II study has demonstrated clinical efficacy and safety of treatment with pomalidomide (POM), with or without low-dose dexamethasone (LoDEX), in patients with relapsed and refractory multiple myeloma (RRMM). The POM+LoDEX combination was generally well tolerated, and it significantly increased the median progression-free survival (4.2 months) when compared with POM alone (2.7 months). The efficacy of POM+LoDEX was not affected by prior treatment indicating that this regimen represents an important new treatment option for patients with RRMM who had received multiple prior therapies.
References
Richardson, P. G. et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood 10.1182/blood-2013-11-538835
Rights and permissions
About this article
Cite this article
A new treatment option for relapsed and refractory MM. Nat Rev Clin Oncol 11, 120 (2014). https://doi.org/10.1038/nrclinonc.2014.11
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.11